Related Experiment Video
Updated: Jul 13, 2026

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
Published on: May 18, 2021
Hepatitis C and steatosis
1Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
Insights
Hepatitis C infection and fatty liver disease often coexist. Managing weight may reduce liver fat and fibrosis, but its impact on antiviral treatment response requires further study.
Area of Science:
- Hepatology
- Virology
- Metabolic Syndrome
Background:
- Hepatitis C infection and non-alcohol-related hepatic steatosis are prevalent global liver diseases.
- These conditions frequently co-occur, with Hepatitis C virus (HCV) genotype 3 directly causing steatosis, while insulin resistance drives steatosis in non-genotype 3 infections.
- Insulin resistance, obesity, hyperglycemia, hypertriglyceridemia, hypertension, and low HDL are common in chronic hepatitis C.
Purpose of the Study:
- To explore the distinct clinical and prognostic implications of liver steatosis in Hepatitis C virus (HCV) infection.
- To review the role of insulin resistance and obesity in the development and progression of steatosis in HCV patients.
- To assess the potential benefits of weight management on steatosis and fibrosis in the context of HCV infection.
Main Methods:
- Literature review and synthesis of existing evidence on HCV, hepatic steatosis, and insulin resistance.
- Analysis of the impact of increased adiposity and steatosis on fibrosis progression and antiviral treatment response.
- Evaluation of studies investigating weight management interventions in patients with HCV and steatosis.
Main Results:
- HCV genotype 3 directly induces hepatic steatosis.
- Insulin resistance is a key factor in steatosis development for non-genotype 3 chronic hepatitis C.
- Increased adiposity and steatosis are linked to accelerated fibrosis progression and reduced response to antiviral therapy.
Conclusions:
- Liver steatosis in HCV infection is a distinct entity with significant clinical and prognostic implications.
- Weight management shows promise in reducing steatosis and improving fibrosis severity in HCV patients.
- Further research is needed to confirm if weight reduction enhances response to antiviral therapy for Hepatitis C.
Abstract:
Hepatitis C infection and non-alcohol-related hepatic steatosis are the most common liver diseases worldwide, and both conditions often co-exist in the same patient. Hepatitis C virus (HCV) genotype 3 directly induces development of steatosis, whereas in patients with non-genotype 3 chronic hepatitis C infection, insulin resistance plays a key role in the pathophysiology of steatosis. Insulin resistance and its clinical components including obesity, hyperglycemia, hypertriglyceridemia, increased blood pressure, and low HDL-cholesterol levels are often seen in patients with chronic hepatitis C infection. Both increased adipocity and presence of steatosis may increase the risk of fibrosis progression, and both have been associated with a decreased rate of response to antiviral treatment. Hence, liver steatosis in the setting of HCV infection is a distinct condition with specific clinical and prognostic implications. Accumulating evidence suggests that weight management may lead not only to a decrease in steatosis but also improvement in fibrosis severity. However, further studies are necessary to determine whether weight reduction improves response to antiviral therapy.
Related Concept Videos
Hepatitis
Cirrhosis II: Pathophysiology
Cirrhosis I: Introduction
Viral Hepatitis I: Introduction
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Chronic Pancreatitis II: Pathophysiology

